Breaking Finance News

Collegium Pharmaceutical Inc (NASDAQ:COLL) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.

Displaying a price of $18.19, Collegium Pharmaceutical Inc (NASDAQ:COLL) traded 3.00% higher on the day. With the last close up 25.11% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same time period. The company has recorded a 50-day moving average of $13.29 and a 200-day moving average of $14.54. 378,623 shares of Collegium Pharmaceutical Inc exchanged hands, up from an average trading volume of 235,834

Zacks Investment Research has upgraded Collegium Pharmaceutical Inc (NASDAQ:COLL) to Hold in a report released on Wednesday October 12, 2016.

Previously on 9/13/2016, Gabelli reported about Collegium Pharmaceutical Inc (NASDAQ:COLL) bumped up the target price from $0.00 to $25.00. At the time, this suggested an upside of 1.80%.

See Chart Below

Collegium Pharmaceutical Inc (NASDAQ:COLL)

Collegium Pharmaceutical Inc has a with a 52 week low of $8.24 and a 52 week high of $30.58 Collegium Pharmaceutical Inc’s market capitalization is currently $0.

General Company Details For Collegium Pharmaceutical Inc (NASDAQ:COLL)

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. The Company's lead product candidate, Xtampza ER (Xtampza), is an abuse-deterrent, extended-release, oral formulation of oxycodone, a prescribed opioid medication. The Company's DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing and/or dissolving, and then taking them orally or snorting or injecting them. It also focuses on development program for COL 195, an abuse deterrent, extended release hydrocodone for the treatment of chronic pain. It is focusing on COL 171, a preclinical DETERx extended release, abuse deterrent methylphenidate formulation for the treatment of ADHD.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *